MY173378A - Efficient lipid delivery to human tear film using a salt-sensitive emulsion system - Google Patents

Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Info

Publication number
MY173378A
MY173378A MYPI2014001672A MYPI2014001672A MY173378A MY 173378 A MY173378 A MY 173378A MY PI2014001672 A MYPI2014001672 A MY PI2014001672A MY PI2014001672 A MYPI2014001672 A MY PI2014001672A MY 173378 A MY173378 A MY 173378A
Authority
MY
Malaysia
Prior art keywords
salt
tear film
sensitive emulsion
emulsion system
human tear
Prior art date
Application number
MYPI2014001672A
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY173378(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MY173378A publication Critical patent/MY173378A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014001672A 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system MY173378A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
MY173378A true MY173378A (en) 2020-01-21

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001672A MY173378A (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Country Status (27)

Country Link
US (2) US9314528B2 (cg-RX-API-DMAC7.html)
EP (5) EP2787969B1 (cg-RX-API-DMAC7.html)
JP (1) JP6142419B2 (cg-RX-API-DMAC7.html)
KR (1) KR102017922B1 (cg-RX-API-DMAC7.html)
CN (2) CN104114152A (cg-RX-API-DMAC7.html)
AR (1) AR089123A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012347459A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014013820A2 (cg-RX-API-DMAC7.html)
CA (1) CA2858574C (cg-RX-API-DMAC7.html)
CL (1) CL2014001518A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990739A2 (cg-RX-API-DMAC7.html)
DK (2) DK2787968T3 (cg-RX-API-DMAC7.html)
ES (2) ES2896336T3 (cg-RX-API-DMAC7.html)
HU (2) HUE049489T2 (cg-RX-API-DMAC7.html)
IL (1) IL233008A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04809A (cg-RX-API-DMAC7.html)
MX (1) MX355216B (cg-RX-API-DMAC7.html)
MY (1) MY173378A (cg-RX-API-DMAC7.html)
PH (2) PH12021553172A1 (cg-RX-API-DMAC7.html)
PL (2) PL2787969T3 (cg-RX-API-DMAC7.html)
PT (2) PT2787968T (cg-RX-API-DMAC7.html)
RU (1) RU2014127074A (cg-RX-API-DMAC7.html)
SG (1) SG11201403013VA (cg-RX-API-DMAC7.html)
SI (2) SI2787968T1 (cg-RX-API-DMAC7.html)
TW (1) TWI652072B (cg-RX-API-DMAC7.html)
WO (2) WO2013086438A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404228B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
SI3266446T1 (sl) 2016-07-07 2019-02-28 Laboratorios Salvat, S.A. Oftalmična sestava, obsegajoča ricinusovo olje in triglicerid s srednjo verigo
JP2019524892A (ja) 2016-08-19 2019-09-05 アクリビスタ エルエルシーAkrivista,Llc ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
CN114376961A (zh) 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
EP3784354A1 (en) 2018-04-27 2021-03-03 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) * 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE69004066T2 (de) 1989-08-03 1994-02-17 Eisai Co Ltd Verfahren zur photostabilisierung von augenspüllösungen.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
WO2000029030A1 (en) 1998-11-13 2000-05-25 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) * 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
RU2291685C2 (ru) 2000-07-14 2007-01-20 Аллерган Инк. Композиции, содержащие терапевтически активные компоненты, обладающие повышенной растворимостью
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
AU2002227206B2 (en) 2000-11-08 2006-09-21 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
BR0306662A (pt) * 2002-10-18 2005-02-22 Joel S Echols Formulação lacrimal de três camadas
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
EP1611883A1 (en) 2003-03-26 2006-01-04 Menicon Co., Ltd. Composition for ophthalmic use
CN100475192C (zh) * 2003-06-13 2009-04-08 爱尔康公司 包含两种聚合物的协同组合的眼用组合物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005046728A1 (ja) * 2003-11-10 2005-05-26 Toray Industries, Inc. 多糖類含有組成物および涙液層安定化点眼剤
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
EP2131809A2 (en) * 2007-02-28 2009-12-16 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
PL2437762T3 (pl) * 2009-06-05 2018-01-31 Allergan Inc Sztuczne łzy i ich zastosowania terapeutyczne
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
CA2858574C (en) 2017-05-30
HK1201458A1 (en) 2015-09-04
EP4403220A3 (en) 2024-10-23
WO2013086449A1 (en) 2013-06-13
US9314528B2 (en) 2016-04-19
EP3981387A1 (en) 2022-04-13
SI2787968T1 (sl) 2020-08-31
WO2013086438A1 (en) 2013-06-13
HK1203057A1 (en) 2015-10-16
CA2858574A1 (en) 2013-06-13
BR112014013820A8 (pt) 2017-06-13
ZA201404228B (en) 2015-12-23
EP2787968B1 (en) 2020-03-04
PH12021553172A1 (en) 2024-05-27
BR112014013820A2 (pt) 2017-06-13
SG11201403013VA (en) 2014-07-30
CO6990739A2 (es) 2014-07-10
RU2014127074A (ru) 2016-02-10
TW201325633A (zh) 2013-07-01
SI2787969T1 (sl) 2021-12-31
ES2797650T3 (es) 2020-12-03
AU2017265181B2 (en) 2019-06-20
JP6142419B2 (ja) 2017-06-07
PT2787968T (pt) 2020-06-16
PH12014501296B1 (en) 2023-04-05
ES2896336T3 (es) 2022-02-24
EP2787969A1 (en) 2014-10-15
EP3666257A1 (en) 2020-06-17
EP2787968A1 (en) 2014-10-15
PL2787968T3 (pl) 2020-08-24
US20130150324A1 (en) 2013-06-13
KR102017922B1 (ko) 2019-09-03
CN108969482A (zh) 2018-12-11
DK2787969T3 (da) 2021-11-01
RU2018119362A (ru) 2018-11-08
MX355216B (es) 2018-04-10
AU2012347459A1 (en) 2014-07-03
IL233008A0 (en) 2014-07-31
HUE057140T2 (hu) 2022-04-28
EP4403220A2 (en) 2024-07-24
RU2018119362A3 (cg-RX-API-DMAC7.html) 2021-09-07
US20130197083A1 (en) 2013-08-01
DK2787968T3 (da) 2020-06-02
PL2787969T3 (pl) 2021-12-20
CN104114152A (zh) 2014-10-22
PT2787969T (pt) 2021-11-09
KR20140107383A (ko) 2014-09-04
CL2014001518A1 (es) 2014-10-24
IL233008A (en) 2017-07-31
PH12014501296A1 (en) 2014-10-08
AR089123A1 (es) 2014-07-30
EP2787969B1 (en) 2021-09-29
MX2014006804A (es) 2014-09-22
JP2015504860A (ja) 2015-02-16
HUE049489T2 (hu) 2020-09-28
AU2017265181A1 (en) 2017-12-14
IN2014CN04809A (cg-RX-API-DMAC7.html) 2015-09-18
TWI652072B (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
MY173378A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
IL260585B (en) Compositions and methods for treating retinal diseases
MY171920A (en) Prevention and treatment of ocular conditions
PH12018500401B1 (en) Antibodies specific for tgf-beta
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
MY183449A (en) Formulations of quinones for the treatment of ophthalmic diseases
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014001118A2 (pt) combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
IN2014MN01551A (cg-RX-API-DMAC7.html)
MX2015001804A (es) Metodos y composiciones para el tratamiento de condiciones relacionadas con la falta del suministro de sangre, choque y lesiones neuronales.
UA111645C2 (uk) Ефективна доставка ліпідів у слізну плівку людини з використанням чутливої до солі емульсійної системи
WO2012105854A3 (en) Compositions for administration to the eye
PL398967A1 (pl) Zastosowanie kwasu loganowego w terapii jaskry
TH127471A (th) องค์ประกอบอิมัลชันทางเภสัชกรรมชนิดน้ำมันต่ำ ซึ่งประกอบด้วยโพรเจสโตเจน
UA93098C2 (en) Liposomal antihelminth agent based on fenasal
UA63268U (uk) Спосіб імуностимуляції у короткозорих людей
NZ623275A (en) Treatment of ocular disease
CL2010000695A1 (es) Composicion oftalmica acuosa que comprende una ciclosporina,glicerina y agua, donde la composicion contiene menos de 0,3% de cloruro de sodio y menos de 0,04% de metabisulfito de sodio; y uso para tratar una condicion ocular.
UA55466U (ru) Способ лечения метаболических нарушений у больных с контузионной травмой глаза